A Phase 3 interventional study of Cellegesic and Placebo in Fissure in Ano and Pain, sponsored by Forest Laboratories. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-11-03.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Anal fissure is a solitary ulcer in the squamous epithelium of the anus causing intense anal pain especially during defecation and for 1 or 2 hours afterwards. There are no approved drugs in the United States (US) for this condition and surgery is often the treatment choice. Strakan is conducting this confirmatory study so the product can be submitted for regulatory approval in the US. Strakan currently markets this product throughout Europe.
The objective of this study is to determine the effect of nitroglycerin ointment 0.4% (Cellegesic) versus placebo on average pain intensity over every 24 hour period for up to 21 days of treatment in 250 patients.
84 studies on the registry are indexed under Fissure in Ano; 16 are open to participants now.
This study's enrollment of 248 is above the median of 99 across 65 interventional studies indexed under Fissure in Ano.
Browse Fissure in Ano studies →Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
First submitted before Forest Laboratories became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants applied Cellegesic 375 mg ointment containing approximately 1.5 mg of nitroglycerin anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
Drug: Cellegesic
Participants applied placebo 375 mg ointment anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
Drug: Placebo
Cellegesic was supplied as an ointment containing 0.4% w/w nitroglycerin.
Also known as: 0.4% nitroglycerin ointment, Rectogesic
Placebo was supplied as an ointment identical to Cellegesic ointment except that it contained no nitroglycerin.
Change From Baseline in Pain Intensity at Days 14-18
Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale at Baseline and on Days 14 through 18. The average pain rating on Days 14 through 18 was calculated and used to determine the change from Baseline. The left-end of the visual analog scale was labelled "least possible pain" and the right-end of the visual analog scale was labelled "worst possible pain". The pain rating ranged from 0 to 100, with a higher score indicating more pain. A negative change score indicated improvement.
Time frame: Baseline to Day 18
Time to an Improvement in Pain Intensity
Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale (VAS) at Baseline and on each of the 21 treatment days of the study. The left-end of the visual analog scale was labelled "least possible pain" and the right-end of the visual analog scale was labelled "worst possible pain". The pain rating ranged from 0 to 100, with a higher score indicating more pain. Improvement was defined as either a ≥ 50% decrease or a ≥ 10 mm decrease from Baseline in rated pain intensity.
Time frame: Baseline to Day 21
Percentage of Responders
Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale at Baseline and on Days 14 through 18. The average pain rating on Days 14 through 18 was calculated. The left-end of the visual analog scale was labelled "least possible pain" and the right-end of the visual analog scale was labelled "worst possible pain". The pain rating ranged from 0 to 100, with a higher score indicating more pain. A responder was defined as a participant with either a ≥ 50% decrease or a ≥ 10 mm decrease from Baseline in the 24 hour average pain intensity averaged over Days 14 to 18.
Time frame: Baseline to Day 18
| Milestone | Cellegesic (Nitroglycerin 0.4%) | Placebo |
|---|---|---|
| Started | 123 | 125 |
| Received treatment | 123 | 124 |
| Completed | 106 | 113 |
| Not completed | 17 | 12 |
| Withdrew: Adverse event | 9 | 3 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 4 |
| Withdrew: Voluntary withdrawal | 5 | 4 |
| Withdrew: Did not receive treatment | 0 | 1 |
Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale at Baseline and on Days 14 through 18. The average pain rating on Days 14 through 18 was calculated and used to determine the change from Baseline. The left-end of the visual analog scale was labelled "least possible pain" and the right-end of the visual analog scale was labelled "worst possible pain". The pain rating ranged from 0 to 100, with a higher score indicating more pain. A negative change score indicated improvement.
| Units on a scale | Cellegesic (Nitroglycerin 0.4%) | Placebo |
|---|---|---|
| Change From Baseline in Pain Intensity at Days 14-18 | -40.4 ± 3.12 | -34.9 ± 3.04 |
Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale (VAS) at Baseline and on each of the 21 treatment days of the study. The left-end of the visual analog scale was labelled "least possible pain" and the right-end of the visual analog scale was labelled "worst possible pain". The pain rating ranged from 0 to 100, with a higher score indicating more pain. Improvement was defined as either a ≥ 50% decrease or a ≥ 10 mm decrease from Baseline in rated pain intensity.
| Days | Cellegisic (Nitroglycerin 0.4%) | Placebo |
|---|---|---|
| ≥ 50% decrease | 10.7 ± 0.6 | 13.2 ± 0.7 |
| ≥ 10 mm decrease | 6.1 ± 0.5 | 7.2 ± 0.6 |
Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale at Baseline and on Days 14 through 18. The average pain rating on Days 14 through 18 was calculated. The left-end of the visual analog scale was labelled "least possible pain" and the right-end of the visual analog scale was labelled "worst possible pain". The pain rating ranged from 0 to 100, with a higher score indicating more pain. A responder was defined as a participant with either a ≥ 50% decrease or a ≥ 10 mm decrease from Baseline in the 24 hour average pain intensity averaged over Days 14 to 18.
| Percentage of responders | Cellegisic (Nitroglycerin 0.4%) | Placebo |
|---|---|---|
| ≥ 50% decrease | 72.4 | 64.5 |
| ≥ 10 mm decrease | 88.6 | 85.5 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cellegesic (Nitroglycerin 0.4%) | — | 2/123 (1.6%) | 96/123 (78%) |
| Placebo | — | 1/124 (0.8%) | 67/124 (54%) |
| Event | Cellegesic (Nitroglycerin 0.4%) | Placebo |
|---|---|---|
| OsteomyelitisInfections and infestations | 1/123 | 0/124 |
| Anal sphincterotomySurgical and medical procedures | 1/123 | 0/124 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/123 | 1/124 |
| Event | Cellegesic (Nitroglycerin 0.4%) | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 86/123 | 59/124 |
| DizzinessNervous system disorders | 6/123 | 2/124 |
| NauseaGastrointestinal disorders | 2/123 | 5/124 |
| DiarrhoeaGastrointestinal disorders | 4/123 | 4/124 |
| SinusitisInfections and infestations | 3/123 | 1/124 |
Safety population: All participants who received at least 1 application of study medication.
| Age, Categorical(Participants) | Cellegesic (Nitroglycerin 0.4%) | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 114 | 117 | 231 |
| >=65 years | 9 | 7 | 16 |
| Age, Continuous(years) | Cellegesic (Nitroglycerin 0.4%) | Placebo | Total |
|---|---|---|---|
| Mean | 46.5 ± 12.61 | 43.4 ± 13.22 | 45.0 ± 12.99 |
| Sex: Female, Male(Participants) | Cellegesic (Nitroglycerin 0.4%) | Placebo | Total |
|---|---|---|---|
| Female | 58 | 58 | 116 |
| Male | 65 | 66 | 131 |
| Ethnicity (NIH/OMB)(Participants) | Cellegesic (Nitroglycerin 0.4%) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 23 | 31 | 54 |
| Not Hispanic or Latino | 100 | 93 | 193 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cellegesic (Nitroglycerin 0.4%) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 3 | 3 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 21 | 16 | 37 |
| White | 99 | 96 | 195 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 6 | 9 |
No study locations are listed for this record.
The record gives a start of Aug 2007, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 8 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitroglycerin